Clarifying whether MRAP2 variants affect MC4R signaling could have important implications for patient care as the MC4R agonist, setmelanotide, has recently been licensed for use in chronic weight management for genetic obesity syndromes affecting the MC4R pathway [30]. This evidence concerns the gene MC4R and Genetic obesity.